GAMMA Investing’s NewAmsterdam Pharma NAMS Stock Holding History

GAMMA Investing’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-9	Closed	-$305	–	4377
2026 Q2	$305	Buy	+9	New	+$297	﹤0.01%	4046
2026 Q1	–	Sell	-10	Closed	-$351	–	4197
2025 Q4	$351	Buy	+10	New	+$364	﹤0.01%	3946
2025 Q2	–	Sell	-7	Closed	-$143	–	3855
2025 Q1	$143	Buy	+7	New	+$156	﹤0.01%	3772

Other funds holding NAMS

TSMHT

Thurston Springer Miller Herd & Titak Indianapolis, Indiana $61.1M AUM 22.51% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing's NAMS Position: Q3 2026 in Review

GAMMA Investing sold out of NewAmsterdam Pharma (NAMS) in Q3 2026, closing a stake of 9 shares — an estimated $305 sold.

GAMMA Investing first reported a position in NAMS in Q1 2025 and held it in 3 quarters. The position peaked at $351 in Q4 2025. 4 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

GAMMA Investing reported no remaining NewAmsterdam Pharma position as of Q3 2026 after selling out during the quarter.
GAMMA Investing sold 9 NewAmsterdam Pharma shares in Q3 2026, an estimated $305.
GAMMA Investing first reported a position in NewAmsterdam Pharma in Q1 2025 and held it in 3 quarters.
GAMMA Investing's NewAmsterdam Pharma position peaked at $351 in Q4 2025.
4 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.